Author Topic: (Abst.) Rituxan superior to Copaxone, interferon-beta in relapse control and tolerability in RRMS  (Read 52 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8247
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, June 27, 2017:

Quote
Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

Spelman T1, Frisell T2, Piehl F3, Hillert J3.

Author information
1
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden/Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
2
Department of Medicine, Karolinska Institutet, Solna, Sweden.
3
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

OBJECTIVE:

To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or interferon-beta (IFN-β).

METHODS:

A total of 461 patients from the Swedish MS registry in the rituximab arm were propensity score matched on a 1:2 basis with 922 patients from the IFN-β/GA comparator, between April 2005 and November 2015. Annualised relapse rate (ARR) was compared using the Poisson method. A marginal Cox model was used to analyse time to first relapse, 3-month confirmed disability progression and treatment discontinuation in the matched sample. A signed-rank test was used to compare Expanded Disability Status Scale (EDSS) change from baseline.

RESULTS:


Rituximab was associated with a reduction in ARR (0.003; 95% confidence interval (CI) = 0.001, 0.009) relative to IFN-β/GA (0.026; 95% CI = 0.020, 0.033) ( p < 0.001). Rituximab was associated with an 87% reduction in the relapse rate (hazard ratio (HR) = 0.13; 95% CI = 0.04, 0.41) and an 85% reduction in the discontinuation rate (HR = 0.15; 95% CI = 0.11, 0.20) relative to IFN-β/GA. EDSS regression from baseline was greater in the rituximab group at 12 and 24 months.

CONCLUSION:

Rituximab appears to be superior to first-generation disease-modifying treatments (DMTs) with respect to relapse control and tolerability, whereas superiority on disability outcomes is less clear.

The abstract can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
62 Views
Last post November 24, 2016, 08:04:14 am
by agate
0 Replies
53 Views
Last post May 17, 2017, 10:17:02 am
by agate
0 Replies
43 Views
Last post January 19, 2018, 04:31:16 pm
by agate
0 Replies
20 Views
Last post March 19, 2019, 04:23:50 pm
by agate
0 Replies
23 Views
Last post April 26, 2019, 06:48:34 am
by agate